Second hand smoke and breast cancer

MAYWOOD, N.J. -- A new scientific report commissioned by the California Air Resources Board (ARB) has concluded that women exposed to second hand smoke have a higher risk of breast cancer. Reviewing earlier studies, the researchers found a 26% increased risk across all studies with a 90% risk based on newer studies with a better assessment of exposure.

TobacAlert(TM) is Nymox's revolutionary new product that allows concerned individuals to determine second hand smoke exposure by measuring the level of cotinine, a metabolite of nicotine, in urine. The ARB report, Proposed Identification of Environmental Tobacco Smoke as a Toxic Air Contaminant - March 2005, describes cotinine as the "biological marker of choice" for determining second-hand smoke exposure.

TobacAlert(TM) is a quick, accurate and easy to use test that can be done almost anywhere, including at home, the workplace or school and that requires no instruments to use. More information about TobacAlert(TM) is available at www.tobacalert.com.

"I do not believe people understand how much of an impact their smoking can have on those around them. TobacAlert(TM) provides everyone with a simple, easy-to-use way of measuring exposure", said Brian Doyle, Nymox's Global Sales Manager.

TobacAlert(TM) is available at approximately 5,400 CVS/pharmacy(R) stores across the U.S. as well as online at www.cvs.com.

TobacAlert(TM) uses patented technology to provide a semi-quantitative measure of cotinine, a by-product of the body's metabolism of nicotine. Cotinine is widely accepted and commonly used in medical research and public health studies to determine the extent of tobacco product exposure. TobacAlert(TM) is intended only to assess an individual's level of tobacco product exposure and not for any medical treatment purposes.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.